| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1917231 | Maturitas | 2014 | 6 Pages |
Abstract
The discriminant value of both models is at least as good as models used in other medical conditions; hence they can be used to communicate the fracture risk to patients. However, given differences in the estimated risks between FRAX® and GARVAN-FRC, the significance of the absolute risk must be related to country-specific recommended intervention thresholds to inform the patient.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Tineke A.C.M. van Geel, John A. Eisman, Piet P. Geusens, Joop P.W. van den Bergh, Jacqueline R. Center, Geert-Jan Dinant,